The Smallest Available Estradiol Transdermal Patch: A New Treatment Option for the Prevention of Postmenopausal Osteoporosis | Zendy

Abigail Bertonazzi | Zendy; Bridgette Nelson | Zendy; Jamie Salvador | Zendy; Elena Umland | Zendy

Open Access

The Smallest Available Estradiol Transdermal Patch: A New Treatment Option for the Prevention of Postmenopausal Osteoporosis

Author(s) -

Abigail Bertonazzi,

Bridgette Nelson,

Jamie Salvador,

Elena Umland

Publication year - 2015

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/whe.15.64

Subject(s) - transdermal , estrogen , medicine , osteoporosis , transdermal patch , menopause , bone resorption , bone mineral , postmenopausal women , endocrinology , pharmacology

Minivelle® (Noven Therapeutics, LLC, FL, USA) is an estradiol transdermal delivery system that has recently been approved in the USA for prevention of postmenopausal osteoporosis. The decline in estrogen during menopause leads to bone resorption, increasing the risk of fractures. Transdermal estradiol has been shown to increase bone mineral density. Safety studies of transdermal estradiol have shown a decreased risk in cardiovascular disease as compared with oral estrogen therapy. Minivelle is currently the smallest available transdermal estradiol patch, providing the lowest effective dose of estrogen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research